Replies to post #1881 on Can Fite BioPharma Ltd (CANF)

[midastouch017]

"Based on Piclidenoson’s safety and efficacy data revealed in this trial, we plan to approach the U.S. FDA and the European EMA with a protocol for a pivotal Phase III study for drug approval and registration," stated Can-Fite CEO, Dr. Pnina Fishman.

[Ortiz]

“superiority of Piclidenoson as compared to Otezla in the Psoriasis Disability Index (PDI) (20.5% vs. 10.3%, respectively, P<0.05).”

I like it. I like it a lot.

IMO

[Ortiz]

“A linear increase in the response of patients to Piclidenoson was achieved along the study period, on week 48 reaching PASI 50 in 90% of patients, PASI 90 in 10% of patients and PDI improvement in 60% of patients.”

Linear increase. It may not have been superior to otezla, however, i read this as it works just as good but it will take longer than 32 weeks, and without the nasty side effects of Otezla.

IMO